Is Suvretta's Stake Cut and FDA's Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
US$35.78 million while still keeping the company as its largest reported holding, as Arcutis reported strong ZORYVE adoption and FDA acceptance of a supplemental NDA for pediatric use. This combination of a major institutional investor rebalancing its position and a regulatory step toward pediatric expansion highlights how ZORYVE's trajectory is central to Arcutis's investment case. We'll now examine how Suvretta's reduced stake, alongside FDA acceptance of ZORYVE's pediatric filing, could reshape Arcutis's investment narrative. This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality To own Arcutis, you need to believe ZORYVE can sustain broad, profitable adoption across multiple dermatology indications despite concentrated product risk. Suvretta trimming its position does not materially alter the near term focus, which still hinges on commercial execution for ZORYVE and managing spending so growth in prescriptions trans
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Stock Is Up 100% in a Year but Here's Why One Fund Still Sold 1 Million Shares [Yahoo! Finance]Yahoo! Finance
- This Biotech Stock Could Cure Your Portfolio's Pain [Yahoo! Finance]Yahoo! Finance
- Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARQT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar ChaudhuriGlobeNewswire
ARQT
Earnings
- 10/28/25 - Beat
ARQT
Sec Filings
- 12/17/25 - Form 4
- 12/15/25 - Form 144
- 12/8/25 - Form 4
- ARQT's page on the SEC website